发明名称 Caspase inhibitors and uses thereof
摘要 This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R<SUP>1 </SUP>is hydrogen, -CHN<SUB>2</SUB>, R, CH<SUB>2</SUB>OR, CH<SUB>2</SUB>SR, or -CH<SUB>2</SUB>Y; <img id="CUSTOM-CHARACTER-00001" he="2.79mm" wi="6.35mm" file="US07442790-20081028-P00001.TIF" alt="custom character" img-content="character" img-format="tif"/> between R<SUP>3 </SUP>and R<SUP>4 </SUP>represents a single or double bond; Y is an electronegative leaving group; R<SUP>2 </SUP>is CO<SUB>2</SUB>H, CH<SUB>2</SUB>CO<SUB>2</SUB>H, or esters, amides or isosteres thereof; R<SUP>3</SUP>is a group capable of fitting into the S2 subsite of a caspase enzyme; R<SUP>4 </SUP>is a hydrogen or C<SUB>1-6 </SUB>alkyl or R<SUP>3 </SUP>and R<SUP>4 </SUP>taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R<SUP>5 </SUP>are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1beta secretion.
申请公布号 US7442790(B2) 申请公布日期 2008.10.28
申请号 US20070770093 申请日期 2007.06.28
申请人 VERTEX PHARMACEUTICALS, INCORPORATED 发明人 MORTIMORE MICHAEL;MILLER ANDREW;STUDLEY JOHN;CHARRIER JEAN-DAMIEN
分类号 A61K31/404;C07J43/00;A61K31/4015;A61K31/403;A61K31/407;A61K31/435;A61K31/45;A61K31/498;A61K31/5025;A61K31/538;A61K31/54;A61K31/55;A61P1/00;A61P1/04;A61P1/16;A61P1/18;A61P3/00;A61P3/10;A61P7/00;A61P7/06;A61P9/00;A61P9/10;A61P11/00;A61P11/06;A61P13/00;A61P13/12;A61P17/00;A61P17/06;A61P19/00;A61P19/02;A61P19/08;A61P19/10;A61P21/00;A61P21/04;A61P25/00;A61P25/08;A61P25/14;A61P25/16;A61P25/28;A61P27/00;A61P29/00;A61P31/00;A61P31/04;A61P31/12;A61P31/18;A61P35/00;A61P37/00;A61P37/02;A61P37/06;A61P37/08;A61P39/02;A61P43/00;C07D209/86 主分类号 A61K31/404
代理机构 代理人
主权项
地址